Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements
Historical financial data — 41 statements covering FY2018–FY2025
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulatio...
Alnylam Pharmaceuticals, Inc.'s revenue increased 65.2% year over year, from $2.25B to $3.71B.
Net income increased 212.8% over the same period, from $-278.2M to $313.7M.
Over the 7-year period from FY2018 to FY2025, revenue grew by 4858% in total.
Operating cash flow grew 6405.1% to $524.1M.
Alnylam Pharmaceuticals, Inc. maintains a moderate net profit margin of 8.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $1.39B+117.6% | $-302.4M | $1.19B | $-165.8M | $134.0M | $3.84B | N/A | $-165.9M |
| Q1 FY2024 | $494.3M-64.4% | $-65.9M | $439.7M | $-43.4M | $-81.5M | $3.82B | N/A | $-219.3M |
| Q2 FY2024 | $1.15B+133.5% | $-82.8M | $1.03B | $5.2M | $42.6M | $4.01B | N/A | $-3.1M |
| Q3 FY2024 | $1.66B+43.4% | $-194.4M | $1.45B | $-71.7M | $86.3M | $4.21B | N/A | $32.4M |
| Q1 FY2025 | $594.2M-64.1% | $-57.5M | $524.0M | $18.1M | $-118.3M | $4.21B | N/A | $115.4M |
| Q2 FY2025 | $1.37B+130.2% | $-123.8M | $1.16B | $1.9M | $35.4M | $4.57B | N/A | $250.6M |
| Q3 FY2025 | $2.62B+91.3% | $127.3M | $2.21B | $369.9M | $360.5M | $4.85B | N/A | $233.9M |
| Q1 FY2026 | $1.17B-55.4% | $206.0M | $959.7M | $268.6M | $70.5M | $5.13B | N/A | $1.08B |
Balance Sheet Summary (Latest Period)
Total Assets
$4.97B
Total Liabilities
$4.18B
Total Equity
$789.2M
Cash & Equivalents
$2.91B
Total Debt
N/A
Current Assets
$4.05B
Current Liabilities
$1.47B
Retained Earnings
$-6.70B